Shah Sachin A, Sander Stephen, Coleman Craig I, White C Michael
School of Pharmacy, University of Connecticut, Storrs, 06102-5037, USA.
Am J Health Syst Pharm. 2006 Oct 1;63(19):1882-7. doi: 10.2146/ajhp060025.
The optimal delivery medium for esomeprazole magnesium enteric-coated pellets dispersed in various concentrations of Ora-Plus suspension through commonly used nasogastric and gastrostomy tubes using a previously used standardized in vitro protocol was studied.
The study was conducted in two phases. In phase A, 60 size 14 French nasogastric tubes were used to compare esomeprazole pellet delivery via tap water or 30, 50, or 70% Ora-Plus concentrations (15 tubes for each). In phase B, tap water and the concentration that yielded the best pellet delivery from phase A were used with the narrower size 8 and shorter size 20 French tubes. In both phases, the appropriate volume of water was added. All capsules were assumed to have 1,240 pellets. At the end of each administration, pellet retention counts were performed.
The results showed excellent delivery of esomeprazole pellets using water as a medium for tube delivery. When compared with tap water as a delivery medium, no differences in pellet retention were observed when 30% and 50% Ora-Plus were used; thus, these Ora-Plus concentrations are feasible alternatives to tap water for nasogastric tube delivery of esomeprazole pellets.
Administration of esomeprazole magnesium enteric-coated pellets dispersed in tap water or Ora-Plus through size 14 French nasogastric tubes in vitro delivered over 99% of capsule contents, regardless of the Ora-Plus concentration used. For immediate bedside administration, Ora-Plus at 50% concentration is a feasible alternative to water when delivering the pellets through size 14 French tubes, while 30% Ora-Plus is an alternative to water for all tubes studied.
采用先前使用的标准化体外方案，研究将不同浓度的埃索美拉唑镁肠溶微丸分散于Ora-Plus混悬液中，通过常用的鼻胃管和胃造瘘管给药时的最佳给药介质。
本研究分两个阶段进行。在A阶段，使用60根14号法国鼻胃管比较通过自来水或30%、50%或70%浓度的Ora-Plus（每种浓度15根管子）输送埃索美拉唑微丸的情况。在B阶段，使用自来水和A阶段微丸输送效果最佳的浓度，与更细的8号和更短的20号法国管进行比较。在两个阶段，均加入适量的水。所有胶囊均假定含有1240颗微丸。每次给药结束时，进行微丸留存计数。
结果表明，以水作为管道给药介质时，埃索美拉唑微丸的输送效果极佳。与自来水作为给药介质相比，使用30%和50%的Ora-Plus时，微丸留存情况无差异；因此，这些Ora-Plus浓度是鼻胃管输送埃索美拉唑微丸时自来水的可行替代方案。
体外通过14号法国鼻胃管给药时，无论使用何种浓度的Ora-Plus，将埃索美拉唑镁肠溶微丸分散于自来水或Ora-Plus中给药，均可输送超过99%的胶囊内容物。对于床边即时给药，通过14号法国管输送微丸时，50%浓度的Ora-Plus是水的可行替代方案，而30%的Ora-Plus是所有研究管道输送微丸时水的替代方案。
